Insight Molecular Diagnostics Inc, as reported for QQ4 2024, generated revenue of USD 1.49 million with a gross profit of USD 0.98 million, yielding a gross margin of approximately 65.5%. Despite the top-line expansion, the quarter delivered a substantial net loss of USD 33.5 million, driven by sustained operating costs and a sizeable other expense line that dwarfs revenue. EBITDA and operating income were negative at USD -32.9 million and USD -33.6 million respectively, underscoring a high burn rate in a period of limited revenue monetization. The company’s liquidity profile shows USD 10.34 million in cash at period end, aided by a USD 10.84 million financing inflow from common stock issuance, while total debt remains modest at USD 3.66 million and net debt sits at a negative USD 4.97 million due to cash held on hand; however, negative shareholders’ equity (-USD 12.27 million) reflects ongoing equity needs and a fragile balance sheet position.